Related Experiment Video
Updated: May 5, 2026
04:04
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
9.2K
Prolonged initial remission in patients with nodular mixed lymphoma
Annals of Internal Medicine
|May 1, 1984
Summary
This study on nodular mixed lymphoma found a 76% complete response rate, with over half of patients maintaining remission for 7 years. Survival is significantly better for complete responders, highlighting treatment efficacy.
Area of Science:
- Oncology
- Hematology
- Clinical Medicine
Background:
- Nodular mixed lymphoma is a subtype of non-Hodgkin lymphoma.
- Treatment outcomes for nodular mixed lymphoma require further investigation.
Purpose of the Study:
- To evaluate the long-term outcomes of patients with nodular mixed lymphoma treated at the National Cancer Institute.
- To identify prognostic factors influencing survival in nodular mixed lymphoma.
Main Methods:
- Retrospective analysis of 79 patients with nodular mixed lymphoma treated between 1966 and 1978.
- Assessment of complete response rates, duration of remission, and overall survival.
- Correlation of clinical features (stage, B symptoms, bone marrow involvement, LDH levels) with survival outcomes.
Main Results:
- Overall complete response rate was 76%, with 52% of responders maintaining first remission at 7 years.
- Median survival for complete responders exceeded 13 years, compared to less than 2 years for non-responders.
- Advanced stage (III/IV) disease had a 72% complete response rate with remissions lasting over 6 years.
- Prognostic factors like B symptoms, bone marrow involvement, and elevated LDH levels were associated with significantly shorter survival.
Conclusions:
- Nodular mixed lymphoma demonstrates a high complete response rate with durable remissions achievable with various treatment regimens.
- Early identification of prognostic factors is crucial for predicting survival outcomes in nodular mixed lymphoma patients.
- Therapies like C-MOPP chemotherapy can lead to prolonged initial remissions, though late relapses can occur.
